Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
about
Idiosyncratic adverse drug reactions: current conceptsHow we diagnose neutropenia in the adult and elderly patientPharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsExploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case studyLate-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.Role of systems pharmacology in understanding drug adverse events.Neutropenia induced by high-dose intravenous benzylpenicillin in treating neurosyphilis: Does it really matter?Long-term continuous administration of a hydro-ethanolic extract of Synedrella nodiflora (L) Gaertn in male Sprague-Dawley rats: biochemical, haematological and histopathological changes.Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone.Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents.Nonchemotherapy drug-induced neutropenia and agranulocytosis: could medications be the culprit?Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.An overview on the proposed mechanisms of antithyroid drugs-induced liver injury.Understanding chronic neutropenia: life is short.Immune neutropenias of infancy and childhood.Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.How we diagnose and treat neutropenia in adults.Benazepril-Induced Agranulocytosis: A Case Report and Review of the LiteratureClinical Development of Histamine H4 Receptor Antagonists.Non-chemotherapy drug-induced neutropenia - an update.Agranulocytosis Induced by Sinomenine Hydrochloride.Prevalence and clinical significance of neutropenia discovered in routine complete blood cell counts: a longitudinal study.Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus.Non-chemotherapy drug-induced agranulocytosis in a tertiary hospital.An Elderly Woman with Anti-neutrophil Antibody-positive Agranulocytosis Who Responded to High-dose Intravenous Methylprednisolone.Non-Chemotherapy-Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital.Omeprazole-induced blood dyscrasia in a clozapine-treated patient.Ceftobiprole associated agranulocytosis after drug rash with eosinophilia and systemic symptoms induced by vancomycin and rifampicinThe impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes.Hyperoxidation of ether-linked phospholipids accelerates neutrophil extracellular trap formation.Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population.Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program.Sulfasalazine-induced DRESS and severe agranulocytosis successfully treated by granulocyte colony-stimulating factor.Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.Drug-induced agranulocytosis in the Berlin case-control surveillance study.Sepsis and persisting neutropenia in a drug addict.Agranulocytosis Associated with Topiramate: A Case Report and Review of Published Cases.
P2860
Q26824391-DED6960E-2D31-4A31-B75D-F893E1873A20Q26996404-342D2897-766A-4095-A7A9-637EE3C56362Q28066096-CBB9A1C9-7714-43BB-861E-5D041D36B311Q28477582-03C3FBB1-5CA9-4F88-9987-887F27137FBBQ34072947-D1412BDE-2A1C-4641-A589-AF334CB7593EQ34134791-26699FA6-803C-4175-B7FA-DACCE33A7196Q36306153-49547AB5-43B8-4100-A953-6B5411797CD5Q37300313-C7B2E025-0BBF-4ADD-8E44-BDF46D506AF9Q37762809-1990F674-E29C-42F5-B1BD-D1D90F277987Q37991389-D7B0C7BF-4F67-4BE7-AECB-CBA1A8989B0EQ38240000-6C09B696-00F2-4874-8A44-D819261A5D0DQ38271339-33F5983B-AB4A-4117-AA5E-C5142C8985FDQ38383743-00C76401-AA6C-4C48-873D-1B8E47AF9663Q38604646-DB4A4C24-0199-4B54-A46E-66556C1B2D04Q38637993-82726CCB-0BE0-491E-B530-B0FF31AE9070Q38689784-4CE39E2B-C57A-4676-AB4B-BF7A78244C59Q38700289-1E7F7795-D69B-406E-ABDA-1611598857F3Q38874022-3A7B636C-E7EF-4720-B77C-4DF2DED58C46Q38944794-14243E7F-52EF-4D76-A70A-79CFC3636B47Q40063054-AB9563FF-8F64-461A-9B1D-0FB58EA3B871Q40065696-A4436136-93BF-4F6B-BA83-23D807A3CEACQ40081960-CED63B5D-0DCC-4D93-81FF-53CFD6B0E0B2Q40099981-CAEC9621-DE8C-4C65-A509-F24CA386F70EQ40162078-4E068530-FC3D-4F0A-A68D-1C080B4F0167Q41182498-DBE80AE3-ABCF-4EBE-8576-0CF9C031B5D7Q41716811-5A643002-79A5-4CE1-92BA-5D084502D972Q42423427-C2DDEC36-F3C0-4A6F-9F71-22EAAABB4F42Q42610147-034B24A0-AD9E-491F-9703-B7B3D1687B59Q42859202-3CE8BD92-E719-4693-A61A-ABCF3C35C28BQ45780388-BB0F28BC-6E1B-4539-BD3B-B381FA16FFDCQ47104413-C26A9790-87A3-4EBB-A320-60CF92A21EC0Q48026160-2D25CC0C-C428-46CB-9D3E-C4E2568ADD64Q50222018-ABD19314-2758-4235-B078-A93965CA19FFQ50934782-A820B760-689A-4F43-998C-851E4A87AB61Q51119875-6D8F121C-AAE2-4541-BE9A-CCCADE78B67CQ52881571-7F050FE1-CC03-4066-A1EC-B319E4299004Q54458116-007A21E5-C055-421C-8BE0-9B14810B10B5Q55229247-9D103861-60FF-405E-B08B-347A06E4574A
P2860
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@ast
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@en
type
label
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@ast
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@en
prefLabel
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@ast
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@en
P356
P1476
Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management.
@en
P2093
Daniel Tesfa
Marianne Keisu
P2860
P304
P356
10.1002/AJH.21433
P50
P577
2009-07-01T00:00:00Z